Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | EPOR | P19235 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL28501958 | 0.86 | ALDH1A1 (0.59) | SLC1A3SLC1A1LTA4HGSRITGB3 | |
| Lysine SCHEMBL10720682 | 0.85 | ITGB3 (0.60) | ITGB3ITGA2BECE1CPB1CPB2 | |
| Lysine SCHEMBL4185576 | 0.85 | SLC1A3 (0.56) | SLC1A3SLC1A1LTA4HGSRITGB3 | |
| SCHEMBL9195808 | 0.82 | LTA4H (0.60) | SLC1A3SLC1A1LTA4HITGB3ITGA2B | |
| SCHEMBL9195814 | 0.82 | LTA4H (0.60) | SLC1A3SLC1A1LTA4HITGB3ITGA2B | |
| SCHEMBL676143 | 0.81 | LTA4H (0.57) | SLC1A3SLC1A1LTA4HGSRDPP8 | |
| SCHEMBL730307 | 0.81 | LTA4H (0.57) | SLC1A3SLC1A1LTA4HGSRDPP8 | |
| SCHEMBL5816135 | 0.81 | DPP8 (0.69) | SLC1A3SLC1A1DPP8DPP7MMP2 | |
| SCHEMBL464672 | 0.81 | DPP8 (0.69) | SLC1A3SLC1A1DPP8DPP7MMP2 | |
| SCHEMBL453671 | 0.81 | DPP8 (0.69) | SLC1A3SLC1A1DPP8DPP7MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912148-B2 | Methods of treating a disease or condition associated with abnormal angiogenesis | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2014-12-16 | — | — | US | disclosed |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD. | 2012-11-29 | — | — | US | disclosed |
| US-8288349-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-16 | — | — | US | disclosed |
| EP-2368908-A2 | Anti- angiogenic compounds | CovX Technologies Ireland Limited (IE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2089425-B1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LTD (IE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2285415-A1 | ANTI-ANGIOGENIC COMPOUNDS | CovX Technologies Ireland Limited (IE) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009136352-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LTD. (IE) | 2009-11-12 | — | — | WO | disclosed |
| EP-2089425-A2 | ANTI-ANGIOGENIC COMPOUNDS | CovX Technologies Ireland Limited (IE) | 2009-08-19 | — | — | EP | disclosed |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008056346-A2 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | TEK, KDR, FLT4 | SLC1A3 1493/4885SLC1A1 1485/4885LTA4H 2263/4885 |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, FLT4, TEK | SLC1A3 1617/4885SLC1A1 1750/4885LTA4H 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.